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Statins may reduce inflammation and modify vascular risk
R
heumatoid arthritis (RA) is asso-
ciated with accelerated vascular
risk with attendant early mortality
(pooled standardised mortality rate 1.7)
and excess morbidity.1 Optimal treat-
ment of RA disease activity should
therefore reasonably deal with vascular
risk modification in addition to the well
recognised objectives of treatment—
namely, to suppress inflammation,
improve function, prevent articular
damage, and modify psychosocial impli-
cations of disease. Intriguingly, vascular
specialists are now exercised with the
realisation that inflammation is central
to the pathogenesis of atherogenesis.
Striking similarities in the atherogenic
lesion in the vessel have been drawn
with the chronic synovitis characteristic
of RA, particularly to plaque structure
and the role of extracellular matrix
degradation in subsequent rupture.
That said, vascular inflammation is not
reflected in the same degree of local
tissue destruction, nor the sustained
substantial increase in the acute phase
response as in RA, but rather with a
lower grade chronic inflammatory
response relying on high sensitivity
assays for detection of the persistent
inflammatory load. Thus, although not
necessarily exemplary of shared aetiol-
ogy, these parallels suggest that shared
interventions may be possible.
HMG-CoA reductase inhibitors (sta-
tins) reduce cardiovascular morbidity
and mortality by around 25–50% and
are widely used in primary and second-
ary prevention of vascular disease syn-
dromes.2–4 Although operating in part
through lipid modulation, recent studies
demonstrate broader properties for sta-
tins, particularly in altering inflamma-
tory pathways.5 There is considerable
current interest, therefore, in the broa-
der clinical uses of statins, in particular
in disease states more clearly associated
with high grade inflammation.
Many in vitro and animal studies now
describe the potential anti-inflamma-
tory effects of statins. After exposure
to statins, endothelial cells exhibit
increased endothelial nitric oxide
synthase and tissue plasminogen acti-
vator antigen with reduced plasminogen
activator inhibitor 1, tissue factor, and
endothelin expression (reviewed by
Palinski and Napoli6). Macrophage che-
mokine release, chemotactic responses,
and oxidative burst are reduced by
statins, as is NK cell cytotoxicity in
vitro. Antineutrophil cytoplasmic anti-
body-induced neutrophil activation is
also suppressed in vitro.7 Together these
effects suggest that innate immune
responses may be susceptible to inhibi-
tion of HMG-CoA reductase.
‘‘Will the anti-inflammatory effects
of statins in animals be found in
man?’’
Similarly, effects on acquired immune
responses have emerged. Statins sup-
press antigen presenting cell major
histocompatibility complex II expression
through CIITA modulation,8 T cell-
macrophage interactions through leuco-
cyte function antigen-1/intercellular
adhesion molecule-1 (LFA-1/ICAM-1)9
T cell proliferation and interferon c
release, and modify polarisation of
Th1 responses in vitro and in vivo in
rodent models.10 11 In vivo suppressive
effects by various statin moieties have
been described in rodent experimental
allergic encephalomyelitis,12 carageenan
induced inflammation,13 renal ischae-
mia reperfusion injury,14 and transplant
models.15 There is, however, a marked
absence of trial data in man to confirm
these observations in vivo.
Synovial inflammation in RA is simi-
larly characterised by activated compo-
nents of both innate and acquired
immune responses. RA synovitis con-
tains a predominant Th1 response,
widespread macrophage, fibroblast,
mast cell, and B cell activation that in
turn generate high autoantibody pro-
duction (for example, anti-CCP, rheu-
matoid factors) and cytokine release
(for example, tumour necrosis factor a
(TNFa), interleukin (IL)1b, IL6, IL15,
and IL18). Endothelial cell activation,
up regulated adhesion molecule expres-
sion, and angiogenesis are increasingly
recognised. Thus numerous postulated
effects for statins might operate within
the synovial membrane. We have
recently shown in vitro suppression of
synovial T cell and fibroblast-like syno-
viocyte cytokine release by simvastatin,
lending support to this notion.
Moreover, we extended these studies
to show that simvastatin effectively
reduced the severity of rodent collagen
induced arthritis in vivo.10 Ex vivo
analysis in the latter studies showed
suppression of Th1 responses to recall
antigen responses (type II collagen)
without generation of a compensatory
Th2 response. This is in contrast with
studies in experimental allergic ence-
phalomyelitis, in which atorvastatin
induced suppression of Th1 mediated
neurological damage associated with
enhancement of an antigen specific
Th2 response.12 Taken together there is
some evidence on which to build
hypotheses whereby statins might be
useful in the treatment of RA.
Upon what basis might statins be
used in RA? We believe that there are at
least three areas which should be
explored for the use of statins, including
(a) examining vascular risk; (b) as
immune modulators; or more likely (c)
as ‘‘add on’’ treatment to existing
treatments. Moreover, it is likely that
elucidation of downstream molecular
pathways targeted by statins might be
more useful than HMG-CoA reductase
inhibitors themselves in immune mod-
ulation. The existing statins have been
developed for their ability to reduce
cholesterol rather than as dual immune
and lipid modulatory agents. Newer
agents in development may be required
to properly capture this therapeutic
opportunity. One metabolite down-
stream from HMG-CoA reductase—
namely, geranylgeranyl pyrophosphate
(GGPP), excites particular interest.
Numerous investigators have demon-
strated that addition of GGPP to various
models in which statins mediate anti-
inflammatory, antithrombotic, or vascu-
loprotective effects will abrogate such
actions.16–18 This suggests that statins
may inhibit prenylation of signalling
molecules such as the Rho family
GTPases to suppress inflammation, and
that specific prenylation inhibitors may
be useful in autoimmune mediated
inflammation.
POTENTIAL BENEFITS OF
VASCULAR RISK IN RA
Accelerated atherogenesis is a major
cause of morbidity and mortality in
RA. Although RA is not typically asso-
ciated with a raised cholesterol concen-
tration, the characteristic dyslipidaemia
is atherogenic with the common finding
of low high density lipoprotein choles-
terol and small dense atherogenic
low density lipoprotein particles. Inte-
restingly, lipid lowering even within the
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‘‘normal’’ cholesterol range has been
shown to have vascular benefit,2 and
thus a direct coronary heart disease
(CHD) protective pathway in RA for
statins by traditional risk factor mod-
ification is likely.
We recently proposed that cytokine
mediated inflammatory pathways can,
in part, explain increased vascular risk
through accentuation of both classical
(lipids) and new (endothelial function,
insulin resistance) pathways.19 Possibly,
anti-inflammatory mechanisms with
accompanying downstream improve-
ments in new risk factor pathways
may operate for statins. Firstly, statins
could reduce C reactive protein (CRP),
an established independent risk factor
for CHD20; possibly, CRP itself is directly
atherogenic through a range of mechan-
isms.21–24 Secondly, we have shown that
statins suppress IL6 release in vitro.10 A
chronic increase of IL6 may promote
atherogenesis directly through effects in
the vessel wall and indirectly through
secondary effects on, for example, insu-
lin resistance.25
‘‘Statins not only control RA disease
activity but also reduce vascular risk’’
In theory statins could also modify
plasma viscosity, fibrinogen, and ICAM-
1, markers of hypercoagulability and
endothelial activation, respectively, in
patients with active RA. The idea that
the inflammation modulation may alter
vascular risk in RA is emerging. A
recently reported prospective study of
patients with RA suggests that treat-
ment with methotrexate may increase
the length of survival, this being largely
attributable to a reduction in cardiovas-
cular mortality.26 Moreover, it has been
known for some time that corticosteroid
treatment has the surprising effect of
partially reversing insulin resistance in
patients with previously untreated,
active RA.27 Similarly, patients in whom
sulfasalazine has suppressed the inflam-
matory response demonstrate normal-
isation of glucose handling.27 More
recently, TNFa blockade with infliximab
has been shown to improve endothelial
function in patients with RA.28 It may
therefore be argued that suppression of
inflammation not only controls RA
disease activity but also modifies various
recently elucidated pathways whereby
vascular risk is increased in active RA.
STATINS AS IMMUNE
MODULATORS IN
INFLAMMATORY DISEASE IN
MAN
Statins may reduce rejection after solid
organ transplantation by immuno-
modulatory effects; however, published
studies are contradictory and do not
permit firm conclusions. A pilot study of
pravastatin in kidney transplant recipi-
ents showed significantly reduced acute
rejection rates,29 and the same drug
reduced severe rejection with haemo-
dynamic compromise in patients after
cardiac transplantation.30 However, an
international, multicentre, randomised,
placebo controlled trial of fluvastatin
after renal transplantation did not
reduce allograft rejection.31 Further-
more, simvastatin was shown to
increase long term survival and reduce
rates of graft vessel disease in patients
with cardiac transplants, but had no
significant effect on rejection rates in a
4 year follow up study.32
It has been suggested that statins may
be beneficial in multiple sclerosis. A
small, open label, uncontrolled trial of
simvastatin 80 mg daily was recently
reported, demonstrating a reduced
number of gadolinium enhancing mag-
netic resonance imaging lesions in
patients with relapsing-remitting dis-
ease.33 It had no effect on the clinical
relapse rate and clearly larger, more
rigorous studies will be required to
define the role for statin treatment in
this disease.
We recently performed the first pla-
cebo controlled study to examine ther-
apeutic effects and vascular risk factor
modification by statins in a chronic
autoimmune disease.34 In a randomised,
double blind, placebo controlled trial,
we found that atorvastatin (40 mg/day)
suppressed the disease activity score
(,10%), acute phase parameters (CRP
(50%) and erythrocyte sedimentation
rate (28%)), and significantly reduced
the swollen joint count (2.16 joints
relative to placebo change) in patients
with RA presenting with active disease
despite existing disease modifying anti-
rheumatic drug (DMARD) treatment.
Although the magnitude of change with
atorvastatin was modest, a significant
reduction in the disease activity score,
nevertheless, provides the first clinical
indication that pathways targeted by
statins may be useful in the treatment of
inflammatory disease. However, no
effect was observed on other clinical
measures of disease activity, particularly
the Health Assessment Questionnaire,
and larger studies will be required to
determine the extent to which changes
seen in this study will be useful clini-
cally.
In parallel, and as suggested above,
our data clearly demonstrate that statins
are potentially effective in modifying
classical (lipids) and new risk factors of
vascular disease despite the presence of
‘‘high grade’’ inflammation. Indeed,
we noted that atorvastatin reduced
plasma viscosity, fibrinogen, and IL6
STATINS
Lipid lowering
effects
– ↓ LDL–
cholesterol
– ↓ Triglyceride
New risk factors
e.g.
– ↓ ICAM-1
– ↓ Fibrinogen
↓ Systemic
cytokine
load
↓
Synovitis
↓ Atherogenesis
↓ CHD events
DMARDs
Figure 1 Potential mechanisms by which statins could reduce the risk of CHD in patients with RA.
Statins may have a dual benefit in patients with RA. Firstly, their lipid lowering effects should directly
reduce the CHD risk. Secondly, their anti-inflammatory effects, manifest within the synovial joint
and thus acting to reduce systemic cytokine spill, will lead to downstream improvements in new risk
factors, as indicated. Of course, statins may also convey direct anti-inflammatory effects at the
vasculature. DMARD treatment clearly has a greater effect than statins in reducing synovial
inflammation and there is emerging evidence that such treatments also improve new risk factor
status (reviewed by Sattar et al19), and consequently reduce CHD risk.
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concentrations relative to placebo. Thus
potential biphasic benefit in reduced
inflammation and modified vascular
risk may accrue with the use of statins
in RA (fig 1).
Whether distinct effects for different
statins will emerge that are functionally
important is unclear. Distinct function
could arise from discrete pharmacologi-
cal properties—for example, lipid solu-
bility, or from subtleties of chemical
structure—for example, the LFA bind-
ing capacity of lovastatin. More detailed
and extensive analyses of a range of in
vitro and in vivo models are required to
examine such fundamental comparative
issues. Crucial to this will be the
development of new therapeutic moi-
eties based on targeting downstream
pathway studies as discussed above.
Most patients with RA now receive a
combination of DMARDs as the empha-
sis of treatment moves towards the
induction of disease amelioration/remis-
sion together with tissue protection.
Whereas existing DMARD treatment
may partially reverse vascular risk,26
our recent report34 suggests that ator-
vastatin may operate to reduce both
traditional and new vascular risk fac-
tors. Clearly, longitudinal studies are
now required to determine whether
such benefits of statins translate into a
significant reduction of the vascular risk
end point in patients with RA, and if so,
whether this occurs with minimal toxi-
city. Given the dual effects of statins in
RA, it is even possible that the relative
magnitude of benefit from such treat-
ments may be greater in RA than in
non-inflamed controls. Finally, statin
sensitive biochemical pathways offer
further opportunity for the generation
of new disease modifying drugs to treat
chronic inflammatory diseases.
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